We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current ABOS market cap is 184.16M. The company's latest EPS is USD -0.9043 and P/E is -3.52.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -11.37M | -14.25M | -13.14M | -13.48M | -16.04M |
| Net Income | -10.71M | -12.87M | -11.31M | -11.61M | -12.96M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.7M | 1.44M | 0 | 0 | 0 |
| Operating Income | -7.81M | -7.91M | -19.58M | -45.24M | -61.14M |
| Net Income | -7.69M | -7.33M | -100.61M | -42.86M | -52.37M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 203.26M | 196.59M | 187.86M | 177.41M | 286.37M |
| Total Liabilities | 6.61M | 7.81M | 8.78M | 8.53M | 6.1M |
| Total Equity | 196.65M | 188.78M | 179.09M | 168.87M | 280.27M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 7.32M | 44.43M | 230.33M | 196.59M | 310.13M |
| Total Liabilities | 1.34M | 6.37M | 5.15M | 7.81M | 43.15M |
| Total Equity | -11.42M | -18.59M | 225.18M | 188.78M | 266.97M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -23.95M | -35.15M | -10.18M | -21.85M | -34.75M |
| Investing | 59.61M | 39.19M | -41.93M | -30.86M | -122.86M |
| Financing | -277k | 3.91M | N/A | -145k | 122.62M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -6.82M | -7.45M | -17.96M | -35.15M | -43.06M |
| Investing | N/A | N/A | -104.12M | 39.19M | -171.67M |
| Financing | 6.24M | 44.68M | 200.47M | 3.91M | 151.75M |
| Market Cap | 184.16M |
| Price to Earnings Ratio | -3.52 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.75 |
| Price to Book Ratio | 0.69 |
| Dividend Yield | - |
| Shares Outstanding | 57.91M |
| Average Volume (1 week) | 368.93k |
| Average Volume (1 Month) | 278.59k |
| 52 Week Change | -19.70% |
| 52 Week High | 11.3099 |
| 52 Week Low | 1.8101 |
| Spread (Intraday) | 0.29 (8.55%) |
| Company Name | Acumen Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.acumenpharm.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
